Literature DB >> 10974407

The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK.

S Z Abdel-Rahman1, R A El-Zein.   

Abstract

DNA repair plays a critical role in protecting the genome of the cell from the insults of cancer-causing agents such as those found in tobacco smoke. Reduced DNA repair capacity would, therefore, constitute a significant risk factor for smoking-related cancers. Recently, a number of polymorphisms in several DNA repair genes have been discovered, and it is possible that these polymorphisms may affect DNA repair capacity and thus modulate cancer susceptibility in exposed populations. In the current study, we explored the relationship between two polymorphisms in the DNA repair gene XRCC1 (polymorphisms in codons 194 and 399) and the genotoxic response induced by the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). The sister chromatid exchange (SCE) assay was used as a marker of genetic damage. Our results, using whole blood cultures from 47 volunteers, indicated that treatment of cells with 0.24, 0.72 and 1.44 mM of NNK induced a concentration-dependent increase in the mean number of SCE (P<0.001). There was a significant difference (P<0.05) in response to NNK treatment between cells from individuals with the 399Gln allele (either homozygous or heterozygous) and cells from individuals with the homozygous 399 Arg/Arg genotype. Treatment of cells that have the 399Gln allele with 0.24, 0.72 and 1.44 mM NNK resulted in 22.8, 35.8 and 52.8% increases in NNK-induced SCE, respectively. Treatment of cells with the 399 Arg/Arg genotype using the same NNK concentrations resulted in 16.0, 15.5 and 32.6% increases in NNK-induced SCE, respectively. In contrast, no significant difference in NNK-induced SCE was observed between cells with the codon 194 Arg/Arg genotype and cells with the codon 194 Arg/Trp genotype at all concentrations of NNK tested. These data suggest that the Arg399Gln amino acid change may alter the phenotype of the XRCC1 protein, resulting in deficient DNA repair. Our study underscores the important role of polymorphisms in DNA repair genes in influencing the genotoxic responses to environmental mutagens, and justifies additional studies to investigate their potential role in susceptibility to cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10974407     DOI: 10.1016/s0304-3835(00)00532-2

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  46 in total

1.  Nucleotide excision repair polymorphisms and survival outcome for patients with metastatic breast cancer.

Authors:  Mary A Bewick; Robert M Lafrenie; Michael S C Conlon
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-28       Impact factor: 4.553

2.  Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.

Authors:  Rujiao Liu; Xiaoying Zhao; Xin Liu; Zhiyu Chen; Lixin Qiu; Ruixuan Geng; Weijian Guo; Guang He; Jiliang Yin; Jin Li; Xiaodong Zhu
Journal:  Tumour Biol       Date:  2015-08-28

3.  Cytokinesis-blocked micronucleus cytome assay biomarkers identify lung cancer cases amongst smokers.

Authors:  Randa A El-Zein; Michael Fenech; Mirtha S Lopez; Margaret R Spitz; Carol J Etzel
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-05       Impact factor: 4.254

4.  Hodgkin lymphoma risk: role of genetic polymorphisms and gene-gene interactions in DNA repair pathways.

Authors:  Claudia M Monroy; Andrea C Cortes; Mirtha Lopez; Elizabeth Rourke; Carol J Etzel; Anas Younes; Sara S Strom; Randa El-Zein
Journal:  Mol Carcinog       Date:  2011-03-03       Impact factor: 4.784

5.  Smoking modifies the relationship between XRCC1 haplotypes and HPV16-negative head and neck squamous cell carcinoma.

Authors:  Katie M Applebaum; Michael D McClean; Heather H Nelson; Carmen J Marsit; Brock C Christensen; Karl T Kelsey
Journal:  Int J Cancer       Date:  2009-06-01       Impact factor: 7.396

6.  Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt.

Authors:  Vincenzo Formica; Michaela Benassi; Giovanna Del Vecchio Blanco; Elena Doldo; Laura Martano; Ilaria Portarena; Antonella Nardecchia; Jessica Lucchetti; Cristina Morelli; Emilia Giudice; Piero Rossi; Alessandro Anselmo; Pierpaolo Sileri; Giuseppe Sica; Augusto Orlandi; Riccardo Santoni; Mario Roselli
Journal:  Med Oncol       Date:  2018-05-02       Impact factor: 3.064

7.  Genetic polymorphisms of XRCC1 (at codons 194 and 399) in Shiraz population (Fars province, southern Iran).

Authors:  Parisa Mohamadynejad; Mostafa Saadat
Journal:  Mol Biol Rep       Date:  2007-09-14       Impact factor: 2.316

8.  Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India.

Authors:  Leelakumari Sreeja; Volga S Syamala; Vani Syamala; Sreedharan Hariharan; Praveenkumar B Raveendran; R V Vijayalekshmi; Jayaprakash Madhavan; Ravindran Ankathil
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-19       Impact factor: 4.553

9.  Contribution of XPD (Lys751Gln) and XRCC1 (Arg399Gln) polymorphisms in familial and sporadic breast cancer predisposition and survival: an Indian report.

Authors:  Volga S Syamala; Vani Syamala; Hariharan Sreedharan; Praveenkumar B Raveendran; Ratheesan Kuttan; Ravindran Ankathil
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

10.  XRCC1 polymorphisms and breast cancer risk from the New York Site of the Breast Cancer Family Registry: A family-based case-control study.

Authors:  Jennifer Zipprich; Mary Beth Terry; Paul Brandt-Rauf; Greg A Freyer; Yuyan Liao; Meenakshi Agrawal; Irina Gurvich; Ruby Senie; Regina M Santella
Journal:  J Carcinog       Date:  2010-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.